I期临床试验-话题@MedSci

#I期临床试验#

226篇内容 | 3895人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2088725, encodeId=1dec2088e25c1, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验, objectType=article, longId=160421, objectId=524e160421b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=524e160421b4, replyNumber=0, likeNumber=61, createdTime=2019-05-15, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=524e160421b4, moduleTitle=以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=524e160421b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088710, encodeId=f5a42088e1049, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Theravance生物制药宣布TD-8236进入I期临床试验, objectType=article, longId=154603, objectId=73d3154603fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73d3154603fa, replyNumber=0, likeNumber=77, createdTime=2019-10-21, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73d3154603fa, moduleTitle=Theravance生物制药宣布TD-8236进入I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73d3154603fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088729, encodeId=40462088e29ef, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, objectType=article, longId=160650, objectId=909e1606500c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909e1606500c, replyNumber=0, likeNumber=81, createdTime=2019-12-11, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909e1606500c, moduleTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=909e1606500c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088716, encodeId=960b2088e16b2, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Incyte宣布开展Ruxolitinib的III期临床试验, objectType=article, longId=156672, objectId=aeee1566e228, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeee1566e228, replyNumber=0, likeNumber=67, createdTime=2019-03-08, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeee1566e228, moduleTitle=Incyte宣布开展Ruxolitinib的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeee1566e228)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088714, encodeId=2bce2088e14ee, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Spago Nanomedical启动I期临床试验SPAGOPIX01, objectType=article, longId=156441, objectId=ef4d156441d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef4d156441d5, replyNumber=0, likeNumber=76, createdTime=2019-10-02, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef4d156441d5, moduleTitle=Spago Nanomedical启动I期临床试验SPAGOPIX01, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef4d156441d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088712, encodeId=3f1c2088e1210, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, objectType=article, longId=156388, objectId=8ee71563888f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ee71563888f, replyNumber=0, likeNumber=57, createdTime=2019-06-12, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ee71563888f, moduleTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ee71563888f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088735, encodeId=dc8b2088e3568, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=治疗卵巢癌和子宫内膜癌的抗体 - 药物偶联物（ADC）STRO-002将开启I期临床试验, objectType=article, longId=162524, objectId=507e16252443, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=507e16252443, replyNumber=0, likeNumber=65, createdTime=2019-10-03, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=507e16252443, moduleTitle=治疗卵巢癌和子宫内膜癌的抗体 - 药物偶联物（ADC）STRO-002将开启I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=507e16252443)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088730, encodeId=eb752088e30a8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功, objectType=article, longId=161192, objectId=ee9f16119219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee9f16119219, replyNumber=0, likeNumber=62, createdTime=2019-11-28, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee9f16119219, moduleTitle=双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee9f16119219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088737, encodeId=a5aa2088e3789, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, objectType=article, longId=163509, objectId=ad4a1635092f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad4a1635092f, replyNumber=0, likeNumber=66, createdTime=2019-06-28, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad4a1635092f, moduleTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad4a1635092f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088711, encodeId=dd962088e118e, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=艾森新药AC0058美国II期临床试验首例系统性红斑狼疮患者正式入组治疗, objectType=article, longId=154956, objectId=189915495643, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=189915495643, replyNumber=0, likeNumber=77, createdTime=2019-09-02, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=189915495643, moduleTitle=艾森新药AC0058美国II期临床试验首例系统性红斑狼疮患者正式入组治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=189915495643)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088722, encodeId=21c42088e2299, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Biomed Res Int：牙槽嵴成形术中侧向Ramus皮质骨板同时使用颊脂垫衍生细胞和自体骨：I期临床试验, objectType=article, longId=160250, objectId=a20c16025024, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a20c16025024, replyNumber=0, likeNumber=73, createdTime=2019-03-15, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a20c16025024, moduleTitle=Biomed Res Int：牙槽嵴成形术中侧向Ramus皮质骨板同时使用颊脂垫衍生细胞和自体骨：I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a20c16025024)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088719, encodeId=c99a2088e1998, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=【开年大吉】张力教授领衔在《柳叶刀》杂志发表《中国抗肿瘤药物研发的挑战与改变：肿瘤学I期临床试验年度报告》, objectType=article, longId=159598, objectId=808b1595986f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=808b1595986f, replyNumber=0, likeNumber=32, createdTime=2019-10-11, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=808b1595986f, moduleTitle=【开年大吉】张力教授领衔在《柳叶刀》杂志发表《中国抗肿瘤药物研发的挑战与改变：肿瘤学I期临床试验年度报告》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=808b1595986f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088723, encodeId=d75a2088e2357, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始, objectType=article, longId=160342, objectId=a54e16034284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a54e16034284, replyNumber=0, likeNumber=59, createdTime=2019-08-15, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a54e16034284, moduleTitle=治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a54e16034284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088721, encodeId=bfe52088e21df, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Blood：I期临床试验：依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤, objectType=article, longId=159650, objectId=141815965033, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=141815965033, replyNumber=0, likeNumber=73, createdTime=2019-03-16, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=141815965033, moduleTitle=Blood：I期临床试验：依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=141815965033)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088703, encodeId=ba382088e03fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=PLOS ONE：天花疫苗MVA的III期临床试验结果, objectType=article, longId=135459, objectId=662a13545945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=662a13545945, replyNumber=0, likeNumber=53, createdTime=2018-04-19, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=662a13545945, moduleTitle=PLOS ONE：天花疫苗MVA的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=662a13545945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088707, encodeId=61112088e0761, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=HPN424治疗转移性去势抵抗性前列腺癌（mCRPC）的I期临床试验, objectType=article, longId=146129, objectId=b5731461296f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5731461296f, replyNumber=0, likeNumber=46, createdTime=2018-11-11, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5731461296f, moduleTitle=HPN424治疗转移性去势抵抗性前列腺癌（mCRPC）的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5731461296f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088705, encodeId=30b42088e0585, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Vertex在III期临床试验中测试CF三联疗法, objectType=article, longId=136761, objectId=2419136e61db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2419136e61db, replyNumber=0, likeNumber=45, createdTime=2019-03-29, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2419136e61db, moduleTitle=Vertex在III期临床试验中测试CF三联疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2419136e61db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088704, encodeId=32712088e0444, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=AsiDNA 治疗晚期实体瘤的I期临床试验正式启动, objectType=article, longId=136480, objectId=e597136480eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e597136480eb, replyNumber=0, likeNumber=71, createdTime=2018-10-09, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e597136480eb, moduleTitle=AsiDNA 治疗晚期实体瘤的I期临床试验正式启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e597136480eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088697, encodeId=c9ac208869ef7, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=EUR J Cancer：舒尼替尼治疗局部晚期或转移性、间变性甲状腺髓质癌的多中心II期临床试验, objectType=article, longId=124996, objectId=11e112499612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11e112499612, replyNumber=0, likeNumber=50, createdTime=2018-05-12, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11e112499612, moduleTitle=EUR J Cancer：舒尼替尼治疗局部晚期或转移性、间变性甲状腺髓质癌的多中心II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11e112499612)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088694, encodeId=5e3a208869493, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验, objectType=article, longId=124108, objectId=397812410839, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397812410839, replyNumber=0, likeNumber=76, createdTime=2018-04-30, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397812410839, moduleTitle=EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397812410839)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床试验

2020-05-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验

2019-05-15

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Theravance生物制药宣布TD-8236进入I期临床试验

2019-10-21

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

默克Keytruda治疗晚期肝癌的III期临床试验失败告终

2019-12-11

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Incyte宣布开展Ruxolitinib的III期临床试验

2019-03-08

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Spago Nanomedical启动I期临床试验SPAGOPIX01

2019-10-02

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

"PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动

2019-06-12

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

治疗卵巢癌和子宫内膜癌的抗体 - 药物偶联物（ADC）STRO-002将开启I期临床试验

2019-10-03

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功

2019-11-28

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验

2019-06-28

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

艾森新药AC0058美国II期临床试验首例系统性红斑狼疮患者正式入组治疗

2019-09-02

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Biomed Res Int：牙槽嵴成形术中侧向Ramus皮质骨板同时使用颊脂垫衍生细胞和自体骨：I期临床试验

2019-03-15

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

【开年大吉】张力教授领衔在《柳叶刀》杂志发表《中国抗肿瘤药物研发的挑战与改变：肿瘤学I期临床试验年度报告》

2019-10-11

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始

2019-08-15

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Blood：I期临床试验：依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤

2019-03-16

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

PLOS ONE：天花疫苗MVA的III期临床试验结果

2018-04-19

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

HPN424治疗转移性去势抵抗性前列腺癌（mCRPC）的I期临床试验

2018-11-11

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Vertex在III期临床试验中测试CF三联疗法

2019-03-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

AsiDNA 治疗晚期实体瘤的I期临床试验正式启动

2018-10-09

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

EUR J Cancer：舒尼替尼治疗局部晚期或转移性、间变性甲状腺髓质癌的多中心II期临床试验

2018-05-12

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验

2018-04-30

科室
- - 订阅+
  - 更多科室
工具
服务